Drugs / NKA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01846715 | Apr 2013 → Dec 2014 | chronic kidney disease | Tengion | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKA | “Therapeutic intervention with NKA is intended to delay the need for renal replacement therapy (dialysis or transplant) which at this time, is inevitable in patients with CKD.” NCT01846715 ↗ |
| Modality | Cell therapy | “NKA is made from expanded autologous, homologous, selected renal cells (SRC) obtained from the patient's kidney biopsy.” NCT01846715 ↗ |
| Route | Other | “when implanted at one site in a recipient kidney” NCT01846715 ↗ |